Oh yeah, I forgot to add that he said they are running trials now for PPMS and fingolimod. Maybe because they think it is neuroprotective as well? They may be starting trials to try an even lower dose. He was not dismissing the herpes deaths but said they were both on the higher treatment in trials (1.5 mg.), and the prescribed dose will be .5 mg. And the two people delayed getting treatment. He said herpes doesn't scare him as much because of Zovirax and anti-virals. I felt very reassured that he was optimistic but cautious and would carefully monitor his patients on this drug. Again, as it stands now, he thought the safety profile of the unknown fingolimod was a little better than the known risk of PML on Tysabri, especially after 24 months. Somehow that reassured me too. And yes this is a DMD drug not for treating symptoms. I wonder how much the drug company is going to gouge us for these pills. Shots can be up to $2,000 a month. Can you imagine paying $2,000 for a tiny bottle of pills?!